DIACEUTICS PLC

Regulatory Filings • Mar 16, 2022

National Storage Mechanism | Additional information

RNS Number : 8889E

Diaceutics PLC

16 March 2022

16 March 2022

Diaceutics PLC

("Diaceutics" or "the Company" or "the Group")

Diaceutics approved by Centers for Medicare & Medicaid Services for enhanced data access

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces it has been approved by the Centers for Medicare & Medicaid Services (CMS) to receive US medical claims data at an increased frequency. The data will be integrated with Diaceutics' weekly aggregated Lab data within the DXRX diagnostic commercialisation platform, providing enhanced insight into the testing landscape for Precision Medicine.

By increasing the frequency of data feeds, Diaceutics' pharma and diagnostic clients can understand the evolving testing landscape in near real-time,  empowering strategies to drive faster access to the right treatment. This is particularly important when considering the profound impact of the COVID pandemic on the testing for cancer and other diseases.

Diaceutics' data capabilities is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.  Through its powerful data analytics, machine learning and deep disease-level expertise and understanding, Diaceutics transforms data into valuable and actionable insights to build a comprehensive picture of a patient's diagnostic journey and eliminate barriers to treatment.

Peter Keeling, CEO of Diaceutics commented, "The most competitive companies in the diagnostic data space are those that not only can integrate very different large data sets but can deliver near real time customer insights. We have been working with the team at CMS for many years and this step up in data access helps supercharge our service in the market. Reducing the lag time for receipt of data will enable us to draw greater insight and value to help identify the best possible testing journey sooner than is currently possible, meaning treatment can be more timely and effective - a key goal for all involved in Precision Medicine particularly in the wake of COVID's profound disruption to testing for cancer and other rare diseases."

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer	Via Alma PR
Philip White, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFLTVFIELIF